Antimicrobial Resistance During the SARS-CoV-2 (COVID-19) Pandemic

Methodist Health System

Status: Completed

Conditions: COVID-19

Study type: Observational

Funder types: Other

Identifiers

NCT06334731

045.PHA.2021.D

Details and patient eligibility

About

Assess the incidence and rates of resistant pathogens prior to and during the COVID-19 pandemic.

Full description

The COVID-19 pandemic accelerated/exacerbated resistance rates for key pathogens. Specifically, incidence of extended-spectrum beta-lactamase producing Enterobacteriaceae (ESBLPE), carbapenem-resistant bacteria (CRB), methicillin-resistant Staphyloccoccus aureus (MRSA), vancomycin-resistant Enterococci (VRE), and C. difficile infections (CDI) will be higher in the pandemic time period (Pandemic, March 2020 - February 2025) compared to the pre-pandemic period (Pre-Pandemic, March 2018 - February 2020).

Enrollment: 400 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• • Patients admitted to Methodist Richardson, Methodist Mansfield, Methodist Charlton, or Methodist Dallas Medical Centers between March 2018 and August 2021.

  • >18 years old

Exclusion criteria

• • Outpatient visit

  • Not admitted to an inpatient or observation status